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Abstract A2A adenosine receptor antagonists have been
proposed as a new therapy of PD. Since oxidative stress
plays an important role in the pathogenesis of PD, we
studied the effect of the selective A2A adenosine receptor
antagonists 8-(-3-chlorostyryl)caffeine (CSC) and 4-(2-[7-
amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yla-
mino]ethyl)phenol (ZM 241385) on hydroxyl radical
generation, and glutamate (GLU) and dopamine (DA)
extracellular level using a microdialysis in the striatum of
6-OHDA-treated rats. CSC (1 mg/kg) and ZM 241385
(3 mg/kg) given repeatedly for 14 days decreased the
production of hydroxyl radical and extracellular GLU
level, both enhanced by prior 6-OHDA treatment in dial-
ysates from the rat striatum. CSC and ZM 241385 did not
affect DA and its metabolites, 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanilic acid (HVA) extracellular
levels in the striatum of 6-OHDA-treated rats. L-DOPA
(6 mg/kg) given twice daily for two weeks in the presence
of benserazide (3 mg/kg) decreased striatal hydroxyl radi-
cal and glutamate extracellular level in 6-OHDA-treated
rats. At the same time, L-DOPA slightly but significantly
increased the extracellular levels of DOPAC and HVA. A
combined repeated administration of L-DOPA and CSC or
ZM 241385 did not change the effect of L-DOPA on
hydroxyl radical production and glutamate extracellular
level in spite of an enhancement of extracellular DA level
by CSC and elevation of extracellular level of DOPAC and
HVA by ZM 241385. The data suggest that the 6-OHDA-
induced damage of nigrostriatal DA-terminals is related to
oxidative stress and excessive release of glutamate.
Administration of L-DOPA in combination with CSC or
ZM 241385, by restoring striatal DA-glutamate balance,
suppressed 6-OHDA-induced overproduction of hydroxyl
radical.
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Introduction
Parkinson’s disease (PD) is a consequence of specific
progressive neurodegeneration of substantia nigra (SN)
pars compacta dopaminergic neurons accompanied by
depletion of dopamine (DA) in the striatum and SN (Fahn
and Sulzer 2004). The underlying motivation for the search
for new antiparkinsonian drugs stems from limitations of
PD therapy with L-DOPA, e.g., dyskinesias, declining
efficacy in the course of the treatment (Cenci 2007), as well
as L-DOPA toxicity (Chen et al. 2008). Recently, a new
therapy with adenosine A2A receptor antagonists has been
proposed for the treatment of PD (Schwarzschild et al.
2006). Some behavioral studies revealed that A2A antago-
nists alone and in combination with L-DOPA mitigated
motor deficits in animal models of PD (Schwarzschild et al.
2006; Bishnoi et al. 2007; Morelli et al. 2007). The
promising data obtained in non-human primates (Kanda
et al. 1998) helped researchers to launch clinical trials with
A2A antagonists in PD patients (Xu et al. 2005). The
mechanism by which A2A antagonists alleviate parkinso-
nian motor dysfunctions is based on modulation of DA
responses through the existing A2A–D2 receptor interac-
tions (Schwarzschild et al. 2006) and their ability to
modulate GABA release and DA-dependent c-fos
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activation in the indirect striatopallidal pathway (Pollack
and Fink 1995; Ochi et al. 2000). By counteracting D2
receptor function, presynaptic A2A receptors are able to
control corticostriatal glutamatergic transmission (Tozzi
et al. 2007).
Epidemiological studies have indicated an inverse rela-
tionship between the consumption of caffeine, a non-
selective adenosine receptor antagonist, and the risk of
developing PD (Ross et al. 2000; Ascherio et al. 2001). A
protective effect of caffeine and more selective antagonists
of A2A receptors, similar to genetic inactivation of A2A
receptors, was observed in an animal MPTP neurotoxicity
model (Xu et al. 2005; Chen et al. 2007) or in ischemia and
excitotoxic brain injury models (Popoli et al. 2004; Chen
et al. 2007). The mechanism allowing A2A antagonists to
protect dopaminergic neurons has not been fully explained
yet, but a variety of their effects on various types of
neurons, e.g., glutamatergic nerve terminals and glial or
immune cells, suggest its complex nature (Chen et al.
2007). Since oxidative stress is regarded as the main factor
contributing to the etiology of PD, it seems of crucial
importance to find out whether A2A adenosine antagonists
may influence the production of free radicals in nigrostri-
atal neurons.
The present study was aimed at investigating the effi-
cacy of A2A antagonists in counteraction of oxidative stress
resulting from the disturbed DA-glutamate balance in
the animal model of PD based on 6-hydroxydopamine
(6-OHDA) administration. The effectiveness of a syner-
gistic combination of L-DOPA and an A2A antagonist,
shown in animal models (Wardas et al. 2001) and in par-
kinsonian patients (Xu et al. 2005) to counteract symptoms
of PD, points to the usefulness of A2A antagonists as a
supplement to L-DOPA therapy. Therefore, the effect of the
combination of an A2A antagonist and L-DOPA on cellular
production of hydroxyl radicals was also determined with
the use of microdialysis in freely moving animals.
Materials and Methods
Animals
Microdialysis studies were conducted on male Wistar rats
(250–300 g), bred at the Institute of Pharmacology, Polish
Academy of Sciences, Krakow, Poland. The rats were
housed in temperature- and humidity-controlled rooms on a
12-h light/dark cycle, with free access to filtered tap water
and standard pelleted laboratory chow throughout the
study. The experimental procedures and housing conditions
used were in strict accordance with the Polish legal regu-
lations concerning experiments on animals (Dz. U.
05.33.289). All the experimental protocols were approved
by the Local Bioethics Commission for Animal
Experiments.
Drugs
L-3,4-dihydroxyphenylalanine (L-DOPA), 6-hydroxydop-
amine (6-OHDA), 8-(3-chlorostyryl)caffeine (CSC), ben-
serazide, haloperidol, and p-hydroxybenzoic acid (PBA)
were obtained from Sigma-Aldrich (Poznan´, Poland),
whereas 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,
3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) came
from TOCRIS (Warsaw, Poland). All the chemicals used
for HPLC were purchased from Merck (Warsaw, Poland).
L-DOPA and benserazide were dissolved in saline. A
solution of PBA was prepared in an artificial cerebrospinal
fluid (aCSF) and was then adjusted to pH = 7.4 with 0.1 M
NaOH. CSC was initially dissolved in dimethyl sulfoxide
(DMSO; Sigma-Aldrich, Poznan´, Poland) and was then
diluted in at least 20 vols. of the vehicle consisting of a
20:80 v/v mixture of Alkamulus EL-620 (Rhone-Poulenc,
Cranbury, NJ) and a phosphate-buffered saline. ZM
241385 was dissolved in a small amount of DMSO and was
then diluted in Cremophor EL (Sigma-Aldrich, Poznan´,
Poland) and 0.9% NaCl (final concentration: a 15% DMSO
and a 15% Cremophor EL). All injections were made
through an intraperitoneal route (i.p.) 14 days after
6-OHDA administration. CSC (1 mg/kg) and ZM 241385
(3 mg/kg) were given once a day for 13 days. L-DOPA was
given twice a day in a dose of 6 mg/kg, together with
benserazide (3 mg/kg), for 13 days to eliminate diurnal
fluctuations in brain DA level. The last doses of the A2A
receptor antagonists CSC and ZM 241385 were given
20 min before the injection of a challenging dose of
L-DOPA (12 mg/kg) with benserazide (6 mg/kg). Control
animals received respective vehicles.
6-OHDA Lesions
Animals were anesthetized with a combination of ketamine
(75 mg/kg) and xylazine (10 mg/kg) and given an unilat-
eral stereotaxic injection of 12 lg/ll 6-OHDA dissolved in
0.9% NaCl containing 0.05% ascorbic acid into the left
medial forebrain bundle (MFB) by means of BAS (USA)
infusion pump. Stereotaxic injections were placed 1.9 mm
anterior to the interaural line, 1.8 mm lateral to the midline,
and 8.2 mm ventral to the dura, according to the atlas of
Paxinos and Watson (1998). Two weeks after the 6-OHDA
injection, the behavior was assessed by monitoring body
rotations induced by apomorphine (0.05 mg/kg s.c.). The
number of contralateral rotations was recorded for 60 min
and, only animals which made 200 turns in 1 h were
included for further experimental steps.
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Monoamine Levels’ Determination
For the measurement of dopamine (DA), 3,4-dihydroxy-
phenylacetic acid (DOPAC) and homovanilic acid (HVA),
the brain tissue was homogenized in 0.1 M HClO4, cen-
trifuged at 4C for 5 min at 10,000 g, and the supernatant
was filtered through 0.1 lm (Millipore) membranes.
2–5 ll of sample was then injected into high-performance
liquid chromatograph (HPLC) with electrochemical
detection.
In Vivo Microdialysis
The rats were anaesthetized with ketamine (75 mg/kg
i.m.) and xylazine (10 mg/kg i.m.) and placed in a ste-
reotaxic apparatus (David Kopf Instruments, Tujunga,
CA, USA). Their skulls were exposed, and small holes
were drilled for the insertion of microdialysis probes into
the striatum using the following coordinates:1.8 mm
anterior from the bregma; 2.8 mm lateral from the sagittal
suture; and -7.0 mm ventral from the dura (Paxinos and
Watson 1998). Vertical microdialysis probes were con-
structed as described in detail elsewhere (Gołembiowska
et al. 2009). Probe inlets were connected to a syringe
pump (BAS, IN, USA) which delivered an aCSF com-
posed of [mM]: NaCl 147, KCl 4.0, MgCl2 1.0, CaCl2
2.2; pH = 7.4 at a flow rate of 1.5 ll/min. All metal parts
of the aCSF delivery system were replaced with PEEK
components or were passivated with 6 M HNO3. Baseline
samples were collected every 20 min after the washout
period to obtain a stable extracellular neurotransmitter
level. Appropriate drugs were then administered 20 min
before L-DOPA injection given at time 0, as shown in
figures, and dialysate fractions were collected for
240 min. At the end of the experiment, the rats were
killed and their brains were histologically examined to
validate probe placement.
Analytic Procedure
DA, DOPAC, and HVA were analyzed using HPLC with
an electrochemical detection. The level of hydroxyl rad-
icals was estimated as 3,4-dihydroxybenzoic acid (3,4-
DHBA), a product of the spin trap reagent PBA (1 mM)
applied via microdialysis probe. DA and its metabolites
were simultaneously determined in the same fractions of
striatal dialysates. Chromatography was performed using
an LC-10 AD pump (Shimadzu Europa GmbH, Warsaw,
Poland), an LC-4B amperometric detector with a cross-
flow detector cell (BAS, IN, USA), and a BDS-Hypersil
C18 analytical column (3 9 100 mm, 3 lm; Thermo
Electron Corp., UK). The mobile phase consisted of
0.1 M monochloroacetic acid adjusted to pH = 3.7 with
3 M sodium hydroxide, 0.5 mM EDTA, 13 mg/l 1-oc-
tanesulfonic acid sodium salt, a 5.7% methanol, and a
0.8% acetonitrile. The flow rate was 0.5 ml/min, and the
applied potential of a 3-mm glassy carbon electrode was
?600 mV at a sensitivity of 2 nA/V. Concentrations of
all compounds were calculated by comparing their peak
areas with respective standards and were processed by
Chromax 2001 (Pol-Lab, Warsaw, Poland) software run
on a personal computer. The obtained values were not
corrected for in vitro probe recovery, which was
approximately 10–15%.
Glutamate was measured in dialysates (20 ll) after
derivatization with 4-dimethylaminoazobenzene-40-sulfo-
nylchloride (DABS-Cl) at 70C for 12 min, according to
Knecht and Chang (1986). Dabsylated amino acids were
separated on an Ultrasphere ODS (4.6 9 150 mm, 3 lm)
column (Supelco, Poznan´, Poland) by gradient elution,
with solvent A (10 mM citric acid, 4% dimethylformam-
ide) and solvent B (acetonitrile). Dabsylated compounds
were detected by measuring an absorbance at 436 nm using
Beckman Amino Acid System Gold with VIS detection.
Data Analysis
All obtained data are given in absolute numbers. The
statistical significance of differences between experimen-
tal groups was calculated using a one-way ANOVA for
repeated-measures, followed by Tukey’s post-hoc test.
The results were considered statistically significant at P \
0.05.
Results
Effects of 6-OHDA on DA, DOPAC, HVA,
and Glutamate in the Rat Striatum
Unilateral injection of 6-OHDA (12 lg/ll) into the left
medial forebrain bundle produced a substantial damage of
nigrostriatal neurons 2 weeks after administration
Table 1 Tissue content of DA, DOPAC and HVA in the striatum and
substantia nigra of control and 6-OHDA (12 lg/side)-treated rats
Striatum pg/mg w.t. mean ± SEM (n)
Treatment DA DOPAC HVA
Control 11856 ± 823 (8) 1322 ± 78 (8) 774 ± 74 (8)
6-OHDA 93 ± 115 (8)** 62 ± 35 (8)** 77 ± 35 (8)**
Substantia nigra pg/mg w.t. mean ± SEM (n)
Control 1371 ± 80 (10) 342 ± 32 (10) 128 ± 22 (10)
6-OHDA 543 ± 78 (15)** 88 ± 3,8 (15)** 42 ± 3,1 (15)**
** P \ 0.01 versus control
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(Tables 1, 2). The contents of DA, DOPAC, and HVA
were markedly decreased by ca. 99, 95, and 90 percent,
respectively in ipsilateral striatum (Table 1). Significant
decreases in DA, DOPAC, and HVA contents (by 60, 74,
and 67 percent, respectively) were also observed in the left
substantia nigra (Table 1). 6-OHDA injection attenuated
extracellular levels of DA, DOPAC, and HVA (by ca. 91,
99 and 98 percent, respectively) and increased the extra-
cellular level of striatal glutamate (Table 2).
Effects of CSC and ZM 241385 on Hydroxyl Radical
Productions and Extracellular Levels of Glutamate,
DA, DOPAC, and HVA in 6-OHDA Treated Rats
The last doses of CSC (1 mg/kg) and ZM 241385
(3 mg/kg) in animals with nigrostriatal neurons damaged
by 6-OHDA and treated chronically with A2A antagonists
for 13 days significantly decreased the production of
hydroxyl radical (Fig. 1a). Repeated measures of
ANOVA showed a significant effect of treatment
(F3,18 = 9.22, P = 0.0006), a significant effect of time
(F14,252 = 37.24, P = 0), and interaction was found
between the two factors (F42,252 = 7.05, P = 0). Post-
hoc analysis with Tukey’s test showed that hydroxyl
radical level in 6-OHDA-treated animals was signifi-
cantly increased when compared with intact rats
(P \ 0.01). Hydroxyl radical level’s decrease caused by
CSC and ZM 241385 was significant in comparison with
6-OHDA group (P \ 0.05).
The last doses of CSC (1 mg/kg) and ZM 241385
(3 mg/kg) in animals with nigrostriatal neurons damaged by
6-OHDA and treated chronically with A2A antagonists for
13 days did not influence extracellular effects of DA,
DOPAC, and HVA (Fig. 2a, b, c). In contrast, both antago-
nists significantly decreased extracellular level of glutamate,
which was markedly increased in 6-OHDA-treated animals
(Fig. 1b). Repeated measures ANOVA showed a significant
effect of treatment (F3,20 = 41.43, P = 0), but a non-signif-
icant effect of time (F14,280 = 1.01, P = 0.44), and no inter-
action between both factors was found (F42,280 = 0.42,
P = 0.99). Post-hoc analysis with Tukey’s test showed that
glutamate level was significantly decreased by CSC and ZM
241385 (P \ 0.01) in comparison with 6-OHDA group, while
there was a significant increase in glutamate level in animals
with nigrostriatal neurons damaged by 6-OHDA (P \ 0.01
versus naı¨ve animals) (Fig. 1b).
Table 2 Extracellular
concentration of DA, DOPAC,
HVA and glutamate in control
and 6-OHDA (12 lg/side)-
treated rats
** P \ 0.01 versus control
Mean ± SEM (n)
pg/10 ll pmoles/10 ll
Treatment DA DOPAC HVA Glutamate
Control 8.83 ± 0.62 (8) 2478 ± 260 (8) 1788 ± 150 (8) 2.94 ± 0.15 (8)
6-OHDA 0.73 ± 0.06(8)** 31 ± 6 (8)** 29 ± 4 (8)** 6.19 ± 0.55(8)**
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Fig. 1 Effects of CSC (1 mg/kg 9 14) and ZM 241385 (ZM,
3 mg/kg 9 14) on extracellular concentration of 3,4-DHBA (a) and
GLU (b) in the striatum of rats treated with 6-OHDA. The injection of
the last dose of the drug is indicated by an arrow. The data are the
mean ± SEM (n = 6–8). a P \ 0.01 6-OHDA, 6-OHDA ? ZM 3
versus control; P \ 0.05 6-OHDA versus 6-OHDA ? CSC 1,
6-OHDA ? ZM 3. b P \ 0.01 6-OHDA versus control; P \ 0.01
6-OHDA versus 6-OHDA ? CSC 1, 6-OHDA ? ZM 3
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Effects of CSC and ZM 241385 Administered Together
with L-DOPA on Hydroxyl Radical Productions
and Extracellular Levels of Glutamate, DA, DOPAC,
and HVA in 6-OHDA-Treated Rats
The last dose of L-DOPA (12 mg/kg) in rats lesioned with
6-OHDA and treated chronically with L-DOPA (6 mg/kg
twice daily for 13 days) decreased hydroxyl radical pro-
duction to control level. The last doses of CSC and ZM
241385 did not influence the L-DOPA-decreased hydroxyl
radical level (Fig. 3a). There was a significant effect of
treatment (F4,24 = 9.90, P = 0.0001), a significant effect
of time (F14,336 = 47.55, P = 0), and interaction was
found between both factors (F56,336 = 8.85, P = 0). Post-
hoc analysis with Tukey’s test showed that the effect of
L-DOPA on hydroxyl radical level was significant in
comparison with 6-OHDA group (P \ 0.001) (Fig. 3a).
Similarly, a decrease in extracellular level of glutamate
was observed under the influence of L-DOPA. The last
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Fig. 2 Effects of CSC (1 mg/kg 9 14) and ZM 241385 (ZM,
3 mg/kg 9 14) on extracellular concentrations of DA (a), DOPAC
(b), and HVA (c) in the striatum of rats treated with 6-OHDA. The
injection of the last dose of the drug is indicated by an arrow. The
data are the mean ± SEM (n = 6–8). a, b, c P \ 0.01 6-OHDA,
6-OHDA ? CSC 1, 6-OHDA ? ZM 3 versus control
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Fig. 3 Effects of CSC (1 mg/kg 9 14) and ZM 241385 (ZM, 3 mg/
kg 9 14) given in combination with L-DOPA (6 mg/kg 9 14, twice
daily) on extracellular concentrations of 3,4-DHBA (a) and GLU
(b) in the striatum of rats treated with 6-OHDA. The time of injection
of the last doses of CSC, and ZM 241385 given 20 min before
challenging dose of L-DOPA (12 mg/kg) is indicated by an arrow.
The data are the mean ± SEM (n = 6–8). a P\0.01 6-OHDA,
6-OHDA ? L-DOPA, 6-OHDA ? L-DOPA ? CSC 1, 6-OHDA ?
L-DOPA ? ZM 3 versus control. b P \ 0.01 6-OHDA, 6-OHDA ?
L-DOPA, 6-OHDA ? L-DOPA ? CSC 1, 6-OHDA ? L-DOPA ?
ZM 3 versus control
226 Neurotox Res (2012) 21:222–230
123
doses of CSC and ZM 241385 did not change the effect of
L-DOPA on glutamate extracellular level (Fig. 3b). There
was a significant effect of treatment (F4,23 = 49.43,
P = 0), but not effect of time (F14,322 = 0.61, P = 0.86),
and there was no interaction between both factors
(F56,322 = 0.71, P = 0.94). Post-hoc analysis with Tukey’s
test showed that the effects of L-DOPA and a combination
of L-DOPA with CSC 1 and ZM 241385 3 were significant
in comparison with 6-OHDA group (P \ 0.01) (Fig. 3b).
The last dose of L-DOPA (12 mg/kg) in rats lesioned
with 6-OHDA and treated chronically with L-DOPA
(6 mg/kg twice daily for 13 days) markedly increased
extracellular levels of DA, DOPAC, and HVA. The last
dose of CSC (1 mg/kg) in combination with L-DOPA ele-
vated extracellular levels of DA, but did not affect extra-
cellular level of DOPAC and HVA (Fig. 4a, b, c). The last
dose of ZM 241385 (3 mg/kg) in combination with
L-DOPA increased extracellular level of DOPAC and
HVA, while did not change extracellular level of DA
(Fig. 4a, b, c). There was a significant effect of treatment
[DA: F4,25 = 26.09, P = 0; DOPAC: F4,26 = 88.32,
P = 0; HVA: F4,25 = 177.9, P = 0], time [DA: F14,350 =
19.47, P = 0; DOPAC: F14,364 = 12.02, P = 0; HVA:
F14,350 = 8.56, P = 0], and interaction was found between
both factors [DA: F56,350 = 4.10, P = 0; DOPAC
F56,364 = 1,84, P = 0.0005; HVA: F56,350 = 8.56, P = 0].
Post-hoc analysis with Tukey’s test showed that effect of
L-DOPA was significant in comparison with 6-OHDA
group (DA, DOPAC: P \ 0.05, HVA: P \ 0.01) (Fig. 4a,
b, c). The effect of CSC on DA level was significant in
comparison with L-DOPA-treated animals (P \ 0.05). ZM
241385 significantly increased extracellular effect of
DOPAC and HVA in comparison with L-DOPA group
(P \ 0.05) (Fig. 4a, b, c).
Discussion
The findings of the present study indicate that adenosine
A2A receptor antagonists, CSC, and ZM 241385 given
repeatedly in doses that effectively reduced haloperidol-
induced catalepsy (Gołembiowska et al. 2009) inhibited
generation of hydroxyl radical in the striatum of rats with
damaged nigrostriatal neurons. Furthermore, it was shown
that L-DOPA itself also lowered the production of hydroxyl
radical and this effect was not changed by CSC and ZM
241385 administered repeatedly with L-DOPA.
In our study, unilateral administration of 6-OHDA into
the MFB nearly completely damaged nigrostriatal neurons,
as we observed a decrease in striatal extracellular DA level
by ca. 92% and a decrease in extracellular levels of
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Fig. 4 Effects of CSC (1 mg/kg 9 14) and ZM 241385 (ZM, 3 mg/
kg 9 14) given in combination with L-DOPA (6 mg/kg 9 14, twice
daily) on extracellular concentration of DA (a), DOPAC (b), and
HVA (c) of rats treated with 6-OHDA. The time of injection of the
last doses of CSC and ZM 241385 given 20 min before challenging
dose of L-DOPA (12 mg/kg) is indicated by an arrow. The data are
the mean ± SEM (n = 6–8). a P \ 0.01 6-OHDA, 6-OHDA ?
L-DOPA, 6-OHDA ? L-DOPA ? ZM 3 versus control; P \ 0.05
6-OHDA ? L-DOPA ? CSC 1 versus control; P \ 0.05 6-OHDA ?
L-DOPA versus 6-OHDA ? L-DOPA ? CSC 1. b P \ 0.01
6-OHDA, 6-OHDA ? L-DOPA, 6-OHDA ? L-DOPA ? CSC 1,
6-OHDA ? L-DOPA ? ZM 3 vs. control; P \ 0.01 6-OHDA ?
L-DOPA, 6-OHDA ? L-DOPA ? CSC 1, 6-OHDA ? L-DOPA ?
ZM 3 versus 6-OHDA; P \ 0.01 6-OHDA ? L-DOPA ? ZM 3
versus 6-OHDA ? L-DOPA. c P \ 0.01 6-OHDA, 6-OHDA ?
L-DOPA, 6-OHDA ? L-DOPA ? CSC 1, 6-OHDA ? L-DOPA ?
ZM 3 versus control; P \ 0.01 6-OHDA ? L-DOPA, 6-OHDA ?
L-DOPA ? CSC 1, 6-OHDA ? L-DOPA ? ZM 3 versus 6-OHDA;
P \ 0.01 6-OHDA ? L-DOPA ? ZM 3 versus 6-OHDA ? L-DOPA
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DOPAC and HVA by 99% in comparison with sham-
operated animals. Tissue contents of DA, DOPAC, and
HVA also decreased in the striatum (below 90–99%) and in
the substantia nigra (below 60–74%). It indicated that
6-OHDA given into the MFB, damaged not only striatal
DA terminals, but also DA cell bodies in the substantia
nigra. In addition, we found a marked increase in striatal
extracellular glutamate level, which indicates that DA
exerts inhibitory control of glutamate release and deficit in
DA synthesis disturbs glutamate-DA balance. These data
are in line with the results of other authors, who also
observed an increase in glutamate release in brain of rats
injected intracerebrally with 6-OHDA (Meshul et al. 1999,
2000; Jonkers et al. 2002).
It is known that DA is a very good source of free
radicals, which are formed during enzymatic metabolism
of DA by MAO, or by its non-enzymatic autoxidation that
leads to production of very reactive DA quinones and
semi-quinones (Halliwell 2006). However, under condi-
tions of a marked DA deficit, i.e., conditions resembling
late-stage PD, glutamate might be the source of free
radicals. It was found that an excessive release of gluta-
mate from nerve terminals causes overstimulation of
glutamate receptors, calcium overload in cytosol, and
stimulation of intracellular signaling in the process called
excitotoxicity (Dunnet and Bjo¨rklund 1999). An increased
calcium influx into cytosol disturbs mitochondrial func-
tions and in particular the mitochondrial respiratory chain.
This leads to a leakage of superoxide radical from mito-
chondrial complexes and, after cellular defense system
failure, to oxidative stress (Dunnet and Bjo¨rklund 1999).
Our study shows that a marked increase in striatal
extracellular glutamate level under conditions of DA
deficit in rats treated with 6-OHDA might be the reason
for an enhanced formation of hydroxyl radical. Multiple
doses of CSC and ZM 241385 lowered extracellular
glutamate level to values seen in control animals, and at
the same time, they decreased the production of hydroxyl
radical. Thus, we may suggest that the effect of A2A
antagonists on glutamate level and subsequent inhibition
of free radical generation underlies the neuroprotective
mechanism of these drugs. Observations of other authors,
who showed neuroprotective effects of A2A antagonists in
a global and focal cerebral ischemia model (Phillis 1995;
Von Lubitz et al. 1995; Chen et al. 1999; Melani et al.
2003) and glutamate or quinolic acid-induced excitotox-
icity (Popoli et al. 2002; Pintor et al. 2004) are in line
with our data. Similarly, other studies reported that ZM
241385, SCH 58261, and CSC counteracted the kainate
and quinolic acid-induced neuronal damage (Jones et al.
1998; Behan and Stone 2002).
In this study, L-DOPA given repeatedly at low doses
significantly inhibited both the formation of hydroxyl
radical and striatal extracellular glutamate level. L-DOPA
also slightly but significantly increased the extracellular
levels of DA, DOPAC, and HVA in the striatum of rats
with damaged nigrostriatal neurons. These data show that
low doses of L-DOPA administered in the late-stage PD
may restore the disturbed DA-glutamate balance, even
when the concentration of DA does not achieve control
values. In addition, under conditions of a long-term DA
deficit, supersensitive DA receptors stimulated by low
concentration of L-DOPA-derived DA may inhibit over-
active glutamate neurons. The latter observation we have
made is very interesting in the light of controversies related
to L-DOPA toxicity. The argument is that in some in vitro
and in vivo experimental models, e.g., following rotenone
(Nakao et al. 1997) or 6-OHDA administration (Cleren
et al. 1999, Ishida et al. 2000), it was shown that oxidative
stress may be the cause of L-DOPA toxicity. On the other
hand, some reports have indicated neuroprotective effects,
since L-DOPA given systematically acutely or repeatedly,
as well as by intrastriatal infusion, diminished free radical
production in rats with a unilateral 6-OHDA lesion of
nigrostriatal neurons (Camp et al. 2000). The lack of
L-DOPA toxic effects after its long-term administration
was also observed by Fornai et al. (2000) in MPTP-treated
mice. Similar results were reported by Dziewczapolski
et al. (1997) and Kostrzewa et al. (2000) in rats lesioned
with 6-OHDA. In contrast to our earlier study, in which we
showed the formation of free radicals after chronic
L-DOPA administration in the striatum of normal rats, the
results obtained in the present study on rats with damaged
DA neurons indicate neuroprotective properties of
L-DOPA. In our opinion, L-DOPA’s neuroprotective versus
toxic effect depends on the stage of damage to DA neurons,
amount of DA synthesized and the rate of its metabolism.
CSC and ZM 241385 administered into rats in combination
with L-DOPA only slightly and not significantly, enhanced
the production of hydroxyl radical. At the same time, the
extracellular level of L-DOPA-derived DA was increased
by CSC, while ZM 241385 accelerated metabolism of
L-DOPA-derived DA. However, neither DA nor DOPAC or
HVA levels achieved control values in the presence of CSC
or ZM 241385. Furthermore, both drugs were ineffective in
changing the extracellular glutamate level which was
decreased by L-DOPA. Thus, subtle changes in DA syn-
thesis or metabolism may influence the production of free
radicals, but glutamate overflow seems to be critical for
oxidative stress development in the late-stage PD.
Recently, Aguiar et al. (2008) showed that combination of
CSC and L-DOPA-decreased the glutamate release in
6-OHDA-lesioned rats. Furthermore, they reported that
A2A adenosine receptor blockade with CSC significantly
decreased nitrate levels and lipid peroxidation in 6-OHDA-
lesioned rats, pointing to antioxidant effect of the drug.
228 Neurotox Res (2012) 21:222–230
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In summary, the obtained results indicate that neuro-
protective mechanism of A2A antagonists in the late-stage
PD may be related to the inhibitory effect of these drugs
on oxidative stress resulting from glutamate-induced
excitotoxicity.
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